 |
|
|
| |
Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen in the open-label extensions of the DRIVE-AHEAD and DRIVE-FORWARD trials
|
| |
| |
HIV Drug Therapy Glasgow 2022; October 23-26, 2022; Glasgow, United Kingdom and virtually
Graeme Moyle1; Hong Wan2; Fanxia Meng2; Rebeca M. Plank2;
Peter Sklar2*; Rima Lahoulou3
1Chelsea & Westminster Hospital, London, United Kingdom; 2Merck & Co., Inc., Rahway, NJ, USA; 3MSD France, Puteaux, France
* An employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA at the time of the study.
|
| |
|
|
|
|
|
